Hypertension Perspective

• CPAP Oversells and Underperforms The pressure pushers have been undeterred by evidence, says Dr Holley.
  Medscape Critical Care, December 22, 2023
• Mandrola's Top 10 Cardiology Stories of 2023 Obesity drugs, factor XI inhibitors, and procedures such as TAVR, PCI, and TEER are among the top stories of 2023, according to cardiologist John Mandrola, MD.
  theheart.org on Medscape, December 20, 2023
• Should BP Guidelines Be Sex-Specific?   New data show that the risk for CVD death among women increases at lower systolic blood pressures than it does among men.
  Medscape Ob/Gyn, December 18, 2023
• The Top Cardiology Trials of 2023   For this year's review, Bob Harrington and Mike Gibson revisit the major cardiology conferences -- from ACC in New Orleans to AHA in Philly.
  theheart.org on Medscape, December 15, 2023
• Advancing Cardiovascular Health Equity Through Prevention Science This review highlights achieving optimal cardiovascular health via a coordinated multidisciplinary approach. Conscious efforts to improve community engagement and health care policy are needed to mitigate inequities and achieve social justice.
  ACC.org, December 13, 2023
• Change Makers: Bill Meury on Transformative Medicines Bill Meury, president and CEO of Karuna Therapeutics, speaks with WebMD Chief Medical Officer John Whyte, MD, about the differences in drug development in psychiatry and the importance of innovation.
  Medscape, December 06, 2023
• Key Updates in Obesity From AHA 2023   Highlights in obesity from AHA 2023 include an overview of the SELECT and SURMOUNT trials, cost-effectiveness of weight loss therapies, and the association of obesity with the risk for heart failure.
  Medscape, December 06, 2023
• Predicting HF Worsening: Speech Analysis Beats Weighing Scales   Heart failure experts, Ileana Piña and Bill Abraham, discuss the HearO study on the use of AI for detecting congestion remotely and other tips and tricks they have learned over the years.
  theheart.org on Medscape, December 04, 2023
• Dec 01 2023 This Week in Cardiology   More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast.
  theheart.org on Medscape, December 01, 2023
• Fall Updates in Dementia, PD, and Stroke   Christoph Diener discusses interesting neurology studies published in October, spanning hearing loss and cognitive impairment, Parkinson's disease, and stroke.
  Medscape Neurology, November 22, 2023
• Is Metabolically Healthy Obesity an 'Illusion'? Caroline Messer, MD, explains that helping patients with obesity lose weight will help them achieve true metabolic health.
  Medscape Diabetes & Endocrinology, November 21, 2023
• S2 Episode 6: Rare Disease: Is It Membranous Nephropathy?   Join experts Drs Matthew Sparks and Laurence Beck as they discuss the diagnosis and management of membranous nephropathy, a rare kidney disease.
  Medscape, November 21, 2023
• To Anticoagulate or Not in Subclinical AF   John Mandrola and ARTESiA investigator Jeff Healey discuss the results and how they compare with the NOAH-AFNET-6 data on the use of DOACs in patients with short-duration AF.
  theheart.org on Medscape, November 20, 2023
• A Better Way to Control Blood Pressure Follow the example of a primary care practice in Ohio that has successfully achieved > 90% blood pressure control in its patients with hypertension.
  Medscape Internal Medicine, November 17, 2023
• Approval of Tirzepatide for Treating Obesity 'Exciting'   Dr Anne Peters explains why she is excited about the FDA approval of tirzepatide for weight loss.
  Medscape Diabetes & Endocrinology, November 16, 2023
• When to Order Antinuclear Antibodies in Primary Care   Tips from an expert rheumatologist also reveal when not to order ANA and how to interpret the results.
  The Curbsiders, November 14, 2023
• Is It Time for Cardiologists to Treat Obesity?   Cardiologists Michelle O'Donoghue and Nicholas Marston discuss the "game changer" trial at AHA showing that GLP-1 agonist semaglutide reduced CV events in patients with ASCVD and overweight/obesity.
  theheart.org on Medscape, November 13, 2023
• My Pet Peeves About the Current State of Primary Care I know some of these are issues that you all struggle with and I wanted to give a voice to them. I wish I had answers to fix them.
  MDedge, November 13, 2023
• Nov 10 2023 This Week in Cardiology   Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.
  theheart.org on Medscape, November 10, 2023
• AHA 2023 Mandrola's Top Trials to Look for at AHA 2023 Semaglutide’s cardiovascular benefit in SELECT, another sham-PCI trial from the ORBITA investigators, and ARTESiA, which examines anticoagulation in subclinical atrial fibrillation, are the top AHA late-breakers for John Mandrola, MD.
  theheart.org on Medscape, November 07, 2023